Company: PTHS
Filing Date: 2025-08-13
Form Type: 10-Q
Source: 0001753926-25-001326
Chunk: 26

Company: Pelthos Therapeutics Inc.
Filing Date: 2025-08-13
Form: 10-Q
Item: Part I, Item 1
Chunk 26
---
 11,344

    $
    226.80

    Granted

    63,400

    $
    13.00

    Vested

    (4,360
    )
     
    $
    226.80

    Forfeited

    —

    $
    —

    Non-vested at
    June 30, 2024

    70,384

    $
    34.20

The
Company recognized stock-based compensation expense related to option vesting amortization of $341,576 and $366,503 for
three months ended June 30, 2025 and 2024, respectively, which is included in general and administrative expenses in the condensed
consolidated statements of operations. The Company recognized stock-based compensation expense related to option vesting amortization
of $745,497 and $659,055 for six months ended June 30, 2025 and 2024, respectively, which is included in general and
administrative expenses in the condensed consolidated statements of operations.

As
of June 30, 2025, the unamortized stock option expense was $549,822. As of June 30, 2025, the weighted average period for the
unamortized stock compensation to be recognized is 0.62 years.

Warrants

The
following is an analysis of the stock warrant grant activity:

    Weighted
    Average

    Weighted
    Average

    Number
    of
    Shares

    Exercise
        
        Price

    Remaining
    Life

    Stock Warrants

    Outstanding December 31, 2024

    5,500

    $
    75.00

    4.13

    Granted

    —

    —

    —

    Expired

    —

    —

    —

    Exercised

    —

    —

    —

    Outstanding June
    30, 2025

    5,500

    $
    75.00

    3.63

    Exercisable June
    30, 2025

    5,500

    $
    75.00

    3.63

    Weighted
    Average

    Weighted
    Average

    Number

    Exercise
        
        Price

    Remaining
    Life

    Stock Warrants

    Outstanding December 31, 2023

    —

    $
    —